Anaveon

Anaveon is committed to translating immunological insights into life-saving therapies. With the vision of utilizing our expertise in cutting-edge immunology to design and develop treatments that benefit patients and society, the team possesses the skills to realize this therapy and is prepared to introduce Anaveon's first drug into clinical trials. By harnessing the power of cytokines and leveraging protein engineering to orchestrate immune responses, we are creating safe and effective treatments for a variety of serious diseases. Our first drug entering clinical trials is a selective interleukin-2 (IL-2) receptor agonist, which is a fusion protein combining a highly specific anti-IL-2 antibody with IL-2. It has been shown that ANV419 can selectively enhance the function of immune effector cells, making it a potential treatment for a range of cancer types. We are now ready to advance ANV419 into clinical testing, bringing it closer to the patients who need it.